KCI reports positive clinical data for VAC VeraFlo Therapy

KCI has revealed new data that underlines the clinical and economic advantages of its VAC VeraFlo Instillation Therapy.

The clinical and scientific evidence was recently featured during three independent presentations at the Diabetic Limb Salvage Conference in Washington DC and two further presentations at the KCI-sponsored Clinical Symposium on Advances in Skin and Wound Care Conference in Florida.

Data from these studies showed VAC VeraFlo offered a number of benefits compared to traditional VAC negative-pressure wound therapy, including reductions in the key metrics of hospital length of stay, time to wound closure and debridement cost.

Joe Woody, president and chief executive officer of the company, said: "KCI is committed to and invested in the future of VAC VeraFlo Therapy as an alternate treatment option for customers and patients."

KCI is currently undergoing a significant operational evolution with the merger of the company with sister company LifeCell and the newly-acquired Systagenix into a single unified business.